Dana-Farber Cancer Institute researchers will present more than 40 research studies at the 61st American Society of Hematology (ASH) Annual Meeting on December 7-10 in Orlando, Fla. Dana-Farber is home to one of the largest and most respected treatment centers for patients with disorders of the blood and bone marrow. ASH is the world's most comprehensive hematology event, attracting more than 25,000 hematology professionals from around the world.
Scientific updates to be presented at ASH reveal potentially practice changing findings related to stem cell transplant, multiple myeloma, and leukemia treatment. Notable oral presentations by Dana-Farber researchers include:
Title: Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission
Title: AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo
Author: Yu-Tzu Tai, PhD
Session time: Saturday, December 7, 10:00 a.m.
Title: A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies
Title: Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Author: Mark Bustoros, MD
Session time: Monday, December 9, 7:45 a.m.
Title: Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort